The safety of psilocybin-assisted psychotherapy: A systematic review.

IF 4 2区 医学 Q1 PSYCHIATRY
Rosana R Freitas, Efstathia S Gotsis, Alexander T Gallo, Bernadette M Fitzgibbon, Neil W Bailey, Paul B Fitzgerald
{"title":"The safety of psilocybin-assisted psychotherapy: A systematic review.","authors":"Rosana R Freitas, Efstathia S Gotsis, Alexander T Gallo, Bernadette M Fitzgibbon, Neil W Bailey, Paul B Fitzgerald","doi":"10.1177/00048674241289024","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Psilocybin, a classical psychedelic, has been rescheduled for use in psilocybin-assisted psychotherapy for treatment-resistant depression in Australia. While evidence for its use is promising, understanding the associated risks is crucial. Accordingly, this review aims to collate adverse event data from psilocybin-assisted psychotherapy clinical trials and evaluate its definition, way of measurement and reporting.</p><p><strong>Methods: </strong>A systematic method was employed to identify clinical trials related to the use of psilocybin-assisted psychotherapy in clinical populations that reported on adverse events. The quality assessment focused on relevant criteria related to adverse event definition, monitoring and reporting methods.</p><p><strong>Results: </strong>A total of 24 articles were included. The studies reported heterogeneous psilocybin doses, study designs and indications. Physical and psychological adverse events during and after psilocybin sessions were examined, revealing variations in measuring, reporting methods and occurrences. The most common adverse events during and after sessions included elevated blood pressure, headaches, nausea, vomiting, fatigue and anxiety. In addition, both suicidal ideation and behaviour were observed infrequently and mainly in participants with a history of suicidal ideation or suicide attempt(s).</p><p><strong>Conclusion: </strong>The review highlights the need to standardise the defintion of an adverse event, including how they are measured and reported, in psychedelic clinical trials to ensure consistent reporting across studies. In addition, screening participants for suicidality history and ongoing monitoring remains important, given the potential risk identified in the literature. However, based on the available data, the safety of psilocybin-assisted psychotherapy is generally supported, and no deaths were attributed to psilocybin. Nevertheless, cautious optimism is needed due to the preliminary nature and heterogeneity of the safety data.</p>","PeriodicalId":8589,"journal":{"name":"Australian and New Zealand Journal of Psychiatry","volume":" ","pages":"128-151"},"PeriodicalIF":4.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Australian and New Zealand Journal of Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/00048674241289024","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/13 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Psilocybin, a classical psychedelic, has been rescheduled for use in psilocybin-assisted psychotherapy for treatment-resistant depression in Australia. While evidence for its use is promising, understanding the associated risks is crucial. Accordingly, this review aims to collate adverse event data from psilocybin-assisted psychotherapy clinical trials and evaluate its definition, way of measurement and reporting.

Methods: A systematic method was employed to identify clinical trials related to the use of psilocybin-assisted psychotherapy in clinical populations that reported on adverse events. The quality assessment focused on relevant criteria related to adverse event definition, monitoring and reporting methods.

Results: A total of 24 articles were included. The studies reported heterogeneous psilocybin doses, study designs and indications. Physical and psychological adverse events during and after psilocybin sessions were examined, revealing variations in measuring, reporting methods and occurrences. The most common adverse events during and after sessions included elevated blood pressure, headaches, nausea, vomiting, fatigue and anxiety. In addition, both suicidal ideation and behaviour were observed infrequently and mainly in participants with a history of suicidal ideation or suicide attempt(s).

Conclusion: The review highlights the need to standardise the defintion of an adverse event, including how they are measured and reported, in psychedelic clinical trials to ensure consistent reporting across studies. In addition, screening participants for suicidality history and ongoing monitoring remains important, given the potential risk identified in the literature. However, based on the available data, the safety of psilocybin-assisted psychotherapy is generally supported, and no deaths were attributed to psilocybin. Nevertheless, cautious optimism is needed due to the preliminary nature and heterogeneity of the safety data.

裸盖菇素辅助心理治疗的安全性:一项系统评价。
引言:裸盖菇素,一种经典迷幻药,在澳大利亚已被重新安排用于裸盖菇素辅助治疗难治性抑郁症。虽然使用它的证据很有希望,但了解相关风险至关重要。因此,本综述旨在整理来自裸盖菇素辅助心理治疗临床试验的不良事件数据,并对其定义、测量方法和报告进行评估。方法:采用一种系统的方法来确定与使用裸盖菇素辅助心理治疗有关的临床试验,这些临床人群报告了不良事件。质量评价侧重于不良事件定义、监测和报告方法的相关标准。结果:共纳入24篇文献。这些研究报告了不同的裸盖菇素剂量、研究设计和适应症。对裸盖菇素治疗期间和之后的生理和心理不良事件进行了检查,揭示了测量、报告方法和发生率的差异。治疗期间和治疗后最常见的不良事件包括血压升高、头痛、恶心、呕吐、疲劳和焦虑。此外,自杀意念和行为很少被观察到,并且主要发生在有自杀意念或自杀企图史的参与者中。结论:该综述强调了对致幻剂临床试验中不良事件的定义进行标准化的必要性,包括如何测量和报告这些不良事件,以确保各研究报告的一致性。此外,考虑到文献中确定的潜在风险,筛选参与者的自杀史和持续监测仍然很重要。然而,根据现有数据,总体上支持裸盖菇素辅助心理治疗的安全性,并且没有死亡归因于裸盖菇素。然而,由于安全性数据的初步性质和异质性,需要谨慎乐观。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
8.00
自引率
2.20%
发文量
149
审稿时长
6-12 weeks
期刊介绍: Australian & New Zealand Journal of Psychiatry is the official Journal of The Royal Australian and New Zealand College of Psychiatrists (RANZCP). The Australian & New Zealand Journal of Psychiatry is a monthly journal publishing original articles which describe research or report opinions of interest to psychiatrists. These contributions may be presented as original research, reviews, perspectives, commentaries and letters to the editor. The Australian & New Zealand Journal of Psychiatry is the leading psychiatry journal of the Asia-Pacific region.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信